We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Then Merck will face biosimilar competition and likely see sales ... However, many of those programs are testing Keytruda, ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck & Co., Inc. (NYSE ... and become less reliant on the wildly popular blockbuster medication. New medications, such as the pulmonary arterial hypertension medication WINREVAIR, will be crucial ...

Further, the company will continue to develop new drugs that will mitigate this risk. Merck has long been a leader in the pharmaceutical industry. The past five years hardly represent the company ...

Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Gardasil and Winrevair. Merck's diversified pipeline includes promising oncology ...